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Fanconi anemia (FA) is a rare genetic instability syndrome characterized by developmental defects, bonemarrow failure, and a high
cancer risk. Fifteen genetic subtypes have been distinguished. The majority of patients (≈85%) belong to the subtypes A (≈60%),
C (≈15%) or G (≈10%), while a minority (≈15%) is distributed over the remaining 12 subtypes. All subtypes seem to fit within
the “classical” FA phenotype, except for D1 and N patients, who have more severe clinical symptoms. Since FA patients need special
clinical management, the diagnosis should be firmly established, to exclude conditions with overlapping phenotypes. A valid FA
diagnosis requires the detection of pathogenic mutations in a FA gene and/or a positive result from a chromosomal breakage
test. Identification of the pathogenic mutations is also important for adequate genetic counselling and to facilitate prenatal or
preimplantation genetic diagnosis. Here we describe and validate a comprehensive protocol for the molecular diagnosis of FA,
based on massively parallel sequencing. We used this approach to identify BRCA2, FANCD2, FANCI and FANCL mutations in
novel unclassified FA patients.
1. Introduction
Fanconi anemia (FA) is a recessive chromosomal instability
syndrome with diverse clinical symptoms and a high risk
for acute myeloid leukemia and squamous cell carcinoma
of the head and neck region [1]. Clinical suspicion of FA is
mostly based on growth retardation and congenital defects in
combination with life-threatening bone marrow failure
(thrombocytopenia and later pancytopenia), which usually
starts between 5 and 10 years of age. However, the clinical
manifestations of FA patients are highly variable, and there-
fore the FA diagnosis should be confirmed by a positive
chromosomal breakage test and/or pathogenic mutations in
one of the FA genes. Currently, mutations in 15 diﬀerent
genes are known to cause FA, and their gene products act in
a pathway that takes care of specific problems that may arise
during the process of DNA replication [2].
The conventional Sanger sequencing-based mutation
screening approach for FA is time-consuming, costly, and
most importantly may not detect all types of disease-causing
aberrations, such as deep intronic mutations, large deletions,
and amplifications. Furthermore, the existence of FANCD2
pseudogenes obstructs the identification of pathogenic
mutations in this gene when sequencing genomic DNA.
Here, we demonstrate a comprehensive mutation detection
approach for FA based on massively parallel sequencing
(MPS) [3].
2. Methods
We designed an in-solution oligonucleotide hybridization
capture kit (SureSelect, Agilent) targeting the open reading
frames of all FA genes, except for regions that contain
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repetitive and low complexity DNA sequences as assessed by
RepeatMasker (http://www.repeatmasker.org/). All exons-,
3′-, and 5′-UTR-regions, and exon-intron boundaries were
targeted by this approach (the oligonucleotide locations, in
a .BED format, are available upon request). In addition, a
number of other genes involved in cancer predisposition and
routinely screened in our diagnostic lab were included in the
enrichment kit. We used the Illumina GAIIx platform for
sequencing.
To assess the performance of the custom target kit and the
massively parallel sequencing method, we selected FA sam-
ples with a spectrum of diﬀerent types of known variations
(Table 1). The pathogenic mutations in these samples have
previously been identified either by Sanger sequencing or by
multiplex ligation-dependent probe amplification (MLPA)
[4]. One of the samples included in the study was from a
carrier of a BRCA1 mutation. Unique barcode sequences
were used for 11 DNA libraries to allow distinction between
the samples that were run on a single Illumina flow-cell
lane. In addition, to evaluate the sensitivity of the approach,
two DNA samples were pooled before library preparation to
mimic a mosaic condition.
An in-house variation detection pipeline, including a
novel tool for large deletion detection, was used to score for
relevant mutations.
2.1. Library Preparation. For each sample, 1.5 µg of DNAwas
resuspended in 75 µL of TE buﬀer in a Covaris microTube,
and subsequently sheared in a Covaris S220 (Covaris, Inc.
MS, USA) using the following settings: duty cycle = 10%,
Intensity = 5, cycles per burst = 200, time = 360, Set mode =
frequency sweeping, and temperature = 4◦C. Fragmented
DNA containing overhangs is converted into blunt ends
using T4 DNA polymerase and Klenow enzyme (New
England Biolabs) by incubation for 30 minutes at 20◦C. The
DNA sample is then purified with QIAquick PCR purifica-
tion kit (Qiagen) following the manufacturer’s instructions
and eluted in 32 µL of Qiagen elution buﬀer. Next, the
3′ ends of the fragmented DNA are adenylated using Klenow
exonuclease (New England Biolabs) by incubating for 30
minutes at 37◦C. The DNA sample is then purified with
MinElute PCR purification kit (Qiagen) following the
manufacturer’s instructions and eluted in 10 µL of Qiagen
elution buﬀer. Next, Illumina-specific index paired-end
adapters (Illumina) are ligated to the 5′ and 3′ ends of DNA
fragments by incubation with DNA ligase (New England
Biolabs) for 15 minutes at 20◦C. The adapter-ligated DNA
fragments are purified with MinElute PCR purification kit,
and 1 µL is used to assess proper adapter ligation by a control
PCR using InPE 1.0, InPE 2.0, and a random index primer
with the following PCR conditions: 30 sec at 98◦C, 18 cycles
of 10 sec at 98◦C, 30 sec at 65◦C, 30 sec at 72◦C, and a final
step of 5 minutes at 72◦C. The quality and quantity of the
library is evaluated with the Agilent 2100 Bioanalyzer on a
DNA 1000 chip following the manufacturer’s instructions.
For the FA gene enrichment, we used 500 ng of adapter-
ligated library following the manufacturer’s instructions.
Briefly, DNA libraries are incubated with the biotinylated
Table 1: Selected FA samples with mutations previously identified
by Sanger sequencing and multiplex ligation-dependent probe
amplification (MLPA), used for validation of the next-generation
sequencing approach.
Sample
(aﬀected gene)
Allele 1 Allele 2 Reference
Sam 1
(BRCA2)
c.9253dupA — BIC DB#
Sam 2
(FANCA)
c.3558insG — [4]
Sam 3
(FANCG)
c.271–272del c.620delT [4]
Sam 4a
(FANCA)
c.1464C>G c.2632G>C [4]
Sam 4b
(FANCA)
Ex 15–23 del — [4]
Sam 5
(BRCA1)
c.2694dupA — BIC DB#
Sam 6
(FANCC)
c.376–377del c.844-1G>C [4]
Sam 7
(FANCA)
Ex 1–20 del
c.893+920
C>A
[5]
Sam 8
(FANCB)
c.811insT absent [4]
Sam 9
(FANCE)
c.91C>T c.91C>T [4]
Sam 10
(PALB2)
Ex 1–10 del c.1802T>A [6]
Sam 11
(FANCI)
c.2509G>T NF∗ [4]
#Breast cancer information core database available at http://www.research
.nhgri.nih.gov/bic/.
∗NF: not found.
RNA custom SureSelect library “baits” for 16 hours at 60◦C.
Next, DNA library that hybridized to the baits is captured
using magnetic beads (Dynabeads, Invitrogen), washed, and
eluted in elution buﬀer. Primers containing unique bar-
code sequences are used to amplify captured libraries, and
equimolar pooling is performed after quantification on a
bioanalyzer. The eleven pooled DNA libraries were then
sequenced on a single flow cell lane of an Illumina GAIIx
using a 72 cycle multiplex paired-end sequence protocol.
3. Results
Sequence data fromDNA libraries of eleven carriers of muta-
tions in the FA genes: FANCA (4), FANCB (1), FANCC (1),
FANCD1 (1), FANCE (1), FANCG (1), FANCI (1), FANCN
(1), and one individual carrying a mutation in BRCA1, were
generated from an Illumina GAIIx sequencer. An average of
2.8 million unique reads were obtained per library resulting
in a median sequence depth of about 100 fold, with an aver-
age enrichment eﬃciency of >75% (Figure 1). Several types
of disease-causing genetic aberrations were present in the
assayed DNA samples including single nucleotide substi-
tutions, small deletions (1–8 nucleotides), and large dele-
tions (multiple exons). We developed a variation detection
pipeline detecting all these types of aberrations.
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Figure 1: Specifications of 11 DNA libraries pooled and sequenced
on one flow cell lane of an Illumina GAIIx. Numbers on top of
the bars indicate the average sequencing depth obtained for the
individual samples. Blue bars indicate total number of unique reads,
red bars indicate reads that fall on target of the bait design, green
bars indicate reads that fall in target regions covered with at least
20x depth. Sample 4 is a mix of genomic DNA from two individuals
4a and 4b.
3.1. Detection of Single Nucleotide Variations (SNVs) and
Small Insertions/Deletions (Indels). The data analysis pipe-
line for the detection of SNVs and small indels that was
developed is comprised of freely available tools on the web.
An initial quality check of the sequence reads is followed
by mapping the paired-end reads with the Burrows-Wheeler
Aligner (BWA) [14] to the National Center for Biotechnology
Information (NCBI) hg19 build reference genome. Subse-
quently, SNPs and small indels are called using Samtools
[15] and Varscan [16]. The resulting list of variations is
annotated with Annovar [17] that utilizes information from
external databases to generate context around the mutations,
such as amino acid change consequence, location to canon-
ical splice site regions, and information about reference to
dbSNP and frequencies if available. Finally, a manual fil-
tering step is executed to prioritize relevant mutations.
Low-frequency frameshifts and truncating mutations are
considered pathogenic. Unreported nonsynonymous amino
acid variations are analyzed in silico by the pathogenicity
predicting programs, Align-GVGD, Polyphen-2 and SIFT
[7–9] to help assess the damaging eﬀect.
The variation detection frequency for all samples was set
at a minimum of 31% of the reads covering the aberrations
except for sample 4 (pre-library DNA pooling of samples
4a and 4b), for which it was set at 12%. The total number
of variations detected in the samples and the subsequent
reduction in number of variations through filtering is
depicted in Table 2.
Using the variation detection pipeline and filtering
procedure 12 SNVs out of the total of 13 were detected. The
variation that escaped the initial filtering procedure resided
deep in the intronic region; 920 nucleotide upstream of the
exon start site. However, the variation was present in the
initial variation list.
3.2. Detection of Large Insertions/Deletions. Large deletions
are detected by analyzing local read depth. Firstly, a reference
local read depth is established by binning read counts in a
preset sliding window using data from all pooled samples.
The local read depth is also determined for each sample
separately, using the same preset sliding window used for
the reference. A Log2 ratio is calculated for each window by
dividing the local read depth of the sample by the reference.
Normalization is performed through a mean shift to zero.
The copy number data is projected on the open reading
frame (ORF) of the gene and also projected on an exon scale,
where the mean read count is aggregated on a per exon basis.
The large FANCA and PALB2 deletions, previously iden-
tified by MLPA (Table 1), were readily detected using the
MPS data. The DNA from sample 4b that contained a het-
erozygous exon 15 to 23 deletion in FANCA was pooled with
sample 4a before library preparation. As expected, the read
depth Log2 ratio as compared to the reference was approxi-
mately −0.5, which corresponds with a loss of one allele in
a background of four copies. Interestingly, in sample 11 only
one pathogenic nucleotide substitution in FANCI has pre-
viously been identified while the other mutation remained
undetected. Here we show the deletion of the last exon
(exon 38) of the gene as detected by our large indel analysis
tool (Figure 2(d)). We confirmed the deletion by PCR and
Sanger sequencing by using a SNP in the last unaﬀected exon
37 and two sets of primers amplifying up- and downstream
of the breakpoint (Figure 3).
3.3. Identification of Pathogenic Mutations in Unclassified FA
Patients. To investigate if our next-generation sequencing
method also identifies mutations in unclassified FA patients,
we investigated five patients that were sent in for FA muta-
tion screening, without prior knowledge about their gene
defect. Aberrations in the FANC-A, -C, -E, -F, and -G genes
were already excluded in a routine diagnostics analysis by
MLPA and Sanger sequencing. In two patients we identified
known compound heterozygous pathogenic mutations in
BRCA2 and FANCD2. In two other patients, novel homozy-
gous mutations were detected. In one patient (Unc4) a
dinucleotide insertion/duplication in exon 9 of FANCL was
found, which results in a frameshift and a stop codon in exon
14. The other patient (Unc3) showed a missense mutation in
exon 28 of FANCI that changed codon 954 from a cysteine to
a tyrosine. The aﬀected amino acid is highly conserved, up to
fruit fly, suggesting that it may have an important function.
Moreover, in silico analysis by SIFT [9] and Polyphen 2 [8]
predicted the amino acid change to be damaging. All the
identified variations were confirmed by Sanger sequencing,
and the novel variations had a proper segregation within the
family.
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Figure 2: Large detection using next-generation sequence data. Copy number data are projected on an open reading frame (ORF) and on
an exon scale. The ORF scale (upper panel) shows log2 ratios (M) for all exons and introns. Red segments indicate an overlap with an exon
and black segments indicate no overlap with exons. The exon scale (lower panel) only shows the mean log2 ratio per exon with their 25th
and 75th percentile. R plots of large deletion analysis. Deletion of exons 1 to 20 of FANCA (a), exons 1 to 10 of FANCN (b), exons 15 to 23
in FANCA (c), and exon 38 in FANCI (d).
In one patient no pathogenic variants were detected,
although the coding regions of all known FA genes were
covered deep enough to call variants. This suggests that the
patient has a defect in a new FA gene or is not a true FA
patient.
4. Discussion
The mutation detection strategy described here proved to be
eﬃcient for the molecular diagnosis of FA although patients
with mutations in FANCF, -J, -M, -O, and -P were not
included in our study. All the FA mutations identified by
Sanger sequencing were also detected by next-generation
sequencing. Moreover, we discovered a novel large deletion
in the FA-I patient, for whom only one truncating mutation
was previously identified [4]. The exact breakpoint at
nucleotide level could be distinguished as also the intronic
regions of the FA genes were enriched and sequenced. We
confirmed the deletion by PCR and Sanger sequencing,
using a SNP in the last unaﬀected exon and two sets of
primers amplifying the regions up- and downstream of the
breakpoint (Figure 3). Besides this novel large deletion we
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Table 2: Pathogenic mutation detection through filtering.
Sample1
Variants
(total)
Variants
(target genes)
NS/SS2
Not in
dbSNP
FA genes3
Pathogenic
clue4
Sam 1 2535 1579 58 11 4 1
Sam 2 2659 1700 43 6 1 1
Sam 3 2388 1537 40 5 2 2
Sam 5 2490 1570 49 5 4 2
Sam 6 2081 1362 38 5 3 2
Sam 7 2417 1541 34 0 0 05
Sam 8 2267 1416 53 5 3 1
Sam 9 2284 1354 34 4 1 1
Sam 10 2570 1760 51 5 2 1
Sam 11 2277 1491 44 7 2 1
1
Sample 4 is not included in this table, as it is composed of pooled DNA from sample 4a and 4b. Slightly diﬀerent analysis parameters were used for that sample.
2NS: nonsynonymous, SS, splice site.
3Number of variations remaining after filtering for variations in FA genes only.
4pathogenic clues are obtained from in silico analysis using Align-GVGD, Polyphen-2, and SIFT [7–9].
5This patient is a carrier for a large deletion and a deep intronic mutation. The large deletion is detectable by a separate tool, and the intronic variation is
filtered out at this stage.
Heterozygous SNP
Break site
Primer
Exon 37
Exon 37
Exon 38
Exon 38
Figure 3: Confirmation of the large FANCI deletion by Sanger
sequencing. A part of exon 37 with a SNP was amplified with
primers designed either up- or downstream of the deletion break-
point. Sequence analyses resulted in the detection of the SNP (red
arrow) as heterozygous or hemizygous, respectively.
identified large genomic deletions in FANCA (2 samples)
and PALB2 (1 sample). The sensitivity of the method was
demonstrated by mixing two DNA samples prior to library
preparation and enrichment. A deletion of one allele in a
background of four alleles can be detected, suggesting that
the method is even applicable for the classification of mosaic
FA patients. However, a thorough assessment of the method
using serial dilutions with samples harboring large deletions
is required to determine the detection limit of the assay. The
identification of large deletions is essential for FA molecular
diagnostics since about 40% of pathogenic mutations in
the major FA complementation group, FA-A, are caused by
large deletions in FANCA. As large deletions have also been
demonstrated for FANCI (this study) and FANCN [6], it
is plausible that these types of aberrations are present in
other FA samples, which were previously unclassified by
conventional molecular screening methods. Therefore, these
types of mutations should be examined in the standard
molecular diagnostics of FA.
The presence of FANCD2 pseudogenes can complicate
the identification of pathogenic mutations in this gene, as
variations will tend to have a reduced frequency due to the
occurrence of multiple highly similar copies. However, this
diﬃculty can be resolved with bioinformatics by flagging
variations that tend to have lower frequencies than expected
within those regions. In cases where all other FA genes are
excluded for mutations, careful inspection is required
for flagged variations. Deep intronic mutations represent
another type of variation, which are not analyzed with the
classical molecular diagnostics approach. Indeed, the hem-
izygous FANCA c.893+920 C>A mutation in sample 7 was
only identified after a heterozygous large FANCA deletion
was detected by MLPA. This suspected the presence of a
mutation on the other FANCA allele, which was then found
after the FANCA cDNA was analyzed [5].
When we applied our novel molecular diagnostics
approach on unclassified FA patients, we identified patho-
genic mutations in four individuals. All the variations were
confirmed with Sanger sequencing and demonstrated proper
segregation with the disease. Two patients carried biallelic
mutation in BRCA2 and FANCD2, which have been
described previously (Table 3). The remaining two patients
harbored novel homozygous mutations in FANCI and
FANCL; c.G2861A (p.C954Y) and c.755 756insAT
(p.M252fs), respectively. The frameshift mutation in FANCL
results in a stop codon in the last exon of the gene, which
likely produces an mRNA targeted for nonsense mediated
decay. The c.2861G>A substitution in FANCI aﬀects a highly
conserved amino acid and results in a large physiochemical
diﬀerence, which is predicted to have a damaging eﬀect on
the FANCI protein by SIFT and polyphen-2. Nevertheless,
functional studies are required to ultimately classify this
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Figure 4: Prioritization scheme for the detection of disease-causing mutations by next-generation sequencing.
Table 3: Mutation detection in unclassified FA patients.
Sample Gene Mut 1 Eﬀect 1 Mut 2 Eﬀect 2 Note
Unc1 BRCA2 c.T8067A p.C2689X c.9672 9673insA p.I3224fs [10, 11]
Unc2 FANCD2 c.904C>T p.R302W c.2715+1G>A splicing [12, 13]
Unc3 FANCI c.G3041A p.C1014Y c.G3041A p.C1014Y Novel
Unc4 FANCL c.755 756insAT p.M252fs c.755 756insAT p.M252fs Novel
Unc5 — NF∗ — NF∗ — —
Annotations are based on the following transcripts: BRCA2, NM 000059.3; FANCD2, NM 033084.3; FANCI, NM 001113378.1; FANCL, NM 001114636.1.
∗NF = not found.
variation as pathogenic. In one FA sample we could not
detect the disease causing mutations in any of the known
FA genes. This patient might represent a novel FA subtype
and whole-exome sequencing might be a useful approach to
identify the aﬀected gene.
Altogether, inspection of diﬀerent variation types and
inclusion of intronic regions warrants a comprehensive
molecular FA diagnosis. Given the average number of vari-
ations of around 2500 per patient, it appears a diﬃcult task to
recognize the disease-causing mutation(s). Here we propose
a prioritization approach following the recessive mode of
inheritance (Figure 4). When no large deletions are identi-
fied, an initial filtering for nonsynonymous and canonical
splice site variations should be performed. Subsequently,
exclusion of variations in dbSNP and an in-house variant
database with a frequency above 2%, reduces the number of
possible pathogenic variations to less than 4. In cases where
only one heterozygous pathogenic mutation is found, close
examination of variations in intronic- and UTR regions in
the same gene is required. When no pathogenic variations
have been detected, assessment of all unique intronic and
UTR variations is needed. With an ever expanding variant
database of characterized FA patients, the identification of
pathogenic mutations will become less complicated. Never-
theless, the necessity for functional tests, such as retroviral
complementation or transfection, will remain essential to
help assess the pathogenic status of unclassified missense
variants.
In conclusion, multiplexed next-generation sequencing
based on massively parallel sequencing is an eﬀective molec-
ular diagnostics approach for FA. The procedure, performed
on genomic DNA, reduces the turnaround time, number
of assays, and costs for a reliable detection of the disease-
causing mutation. With the ever decreasing costs of enrich-
ment and sequencing procedures, we expect that in the near
future this will be the first test for patients clinically suspected
of FA, thus avoiding labor-intensive chromosomal breakage
assays and reducing turnaround time for FA diagnosis. To
increase the eﬃciency of the molecular diagnosis, genes
involved in other bone marrow failure syndromes (e.g.,
diamond-Blackfan anaemia and Shwachman-diamond syn-
drome) can be included, to be able to diagnose these non-FA
patients that are often referred for FA diagnosis.
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